Pamela Esposito's Insider Trades & SAST Disclosures
Pamela Esposito's most recent trade in Kymera Therapeutics Inc was a trade of 2,500 Common Stock done at an average price of $49 . Disclosure was reported to the exchange on Dec. 2, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Pamela Esposito.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 02 Dec 2024 | 2,500 | 0 | - | 49 | 122,500 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 2,500 | 29,127 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.55 per share. | 02 Dec 2024 | 2,500 | 2,500 | - | 29.6 | 73,875 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2024 | 8,500 | 31,627 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.55 per share. | 17 Sep 2024 | 8,500 | 8,500 | - | 29.6 | 251,175 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 48.75 per share. | 17 Sep 2024 | 7,150 | 0 | - | 48.8 | 348,581 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Sale of securities on an exchange or to another person at price $ 47.75 per share. | 17 Sep 2024 | 6,350 | 7,150 | - | 47.7 | 303,185 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2024 | 5,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 17 Sep 2024 | 5,000 | 13,500 | - | 14.2 | 70,900 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 22 Aug 2023 | 18,600 | 263,436 (0%) | 0% | 20.0 | 372,186 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.30 per share. | 22 Aug 2023 | 13,600 | 277,036 (0%) | 0% | 3.3 | 44,880 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2023 | 13,600 | 91,691 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2023 | 5,000 | 35,750 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 22 Aug 2023 | 5,000 | 282,036 (0%) | 0% | 15.5 | 77,500 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 11 Aug 2023 | 1,400 | 263,436 (0%) | 0% | 20 | 28,000 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 1,400 | 105,291 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.30 per share. | 11 Aug 2023 | 1,400 | 264,836 (0%) | 0% | 3.3 | 4,620 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.63 per share. | 10 Jul 2023 | 17,923 | 265,513 (0%) | 0% | 21.6 | 387,674 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 15,000 | 106,691 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.30 per share. | 10 Jul 2023 | 15,000 | 278,436 (0%) | 0% | 3.3 | 49,500 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 10 Jul 2023 | 5,000 | 283,436 (0%) | 0% | 15.5 | 77,500 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 5,000 | 40,750 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.12 per share. | 10 Jul 2023 | 2,077 | 263,436 (0%) | 0% | 21.1 | 43,866 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 16 May 2023 | 5,966 | 263,436 (0%) | 0% | 18.0 | 107,686 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 40,000 | 269,402 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 09 Dec 2022 | 15,000 | 229,402 (0%) | 0% | 25.0 | 375,450 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 09 Dec 2022 | 15,000 | 244,402 (0%) | 0% | 1.0 | 15,150 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 15,000 | 36,203 | - | - | Employee Stock Option (right to buy) | |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.59 per share. | 16 May 2022 | 3,507 | 229,402 (0%) | 0% | 14.6 | 51,167 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 34,125 | 34,125 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 22,750 | 232,909 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2021 | 12,538 | 51,203 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 33.17 per share. | 20 Jul 2021 | 12,538 | 210,159 (0%) | 0% | 33.2 | 415,885 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 20 Jul 2021 | 12,538 | 222,697 (0%) | 0% | 1.0 | 12,663 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 20 Jul 2021 | 4,862 | 215,021 (0%) | 0% | 1.0 | 4,911 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 33.05 per share. | 20 Jul 2021 | 4,862 | 210,159 (0%) | 0% | 33.0 | 160,689 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2021 | 4,862 | 63,741 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 15 Jul 2021 | 4,600 | 214,759 (0%) | 0% | 1.0 | 4,646 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 4,600 | 68,603 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 33.37 per share. | 15 Jul 2021 | 4,600 | 210,159 (0%) | 0% | 33.4 | 153,502 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,063 | 20,063 | - | - | Stock Option (Right to Buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 51,250 | 51,250 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 34,165 | 210,159 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2021 | 29,273 | 78,930 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 14 Jan 2021 | 29,273 | 205,267 (0%) | 0% | 1.0 | 29,566 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 43.58 per share. | 14 Jan 2021 | 29,273 | 175,994 (0%) | 0% | 43.6 | 1,275,717 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2021 | 20,000 | 108,203 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 14 Jan 2021 | 20,000 | 195,994 (0%) | 0% | 1.0 | 20,200 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 45.02 per share. | 14 Jan 2021 | 20,000 | 175,994 (0%) | 0% | 45.0 | 900,400 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2021 | 5,727 | 73,203 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 14 Jan 2021 | 5,727 | 181,721 (0%) | 0% | 1.0 | 5,784 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 42.38 per share. | 14 Jan 2021 | 5,127 | 175,994 (0%) | 0% | 42.4 | 217,282 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 43.24 per share. | 14 Jan 2021 | 600 | 181,121 (0%) | 0% | 43.2 | 25,944 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2020 | 50,704 | 32,758 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.75 per share. | 23 Dec 2020 | 50,704 | 175,994 (0%) | 0% | 1.8 | 88,732 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.30 per share. | 11 Dec 2020 | 12,590 | 125,290 (0%) | 0% | 3.3 | 41,547 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2020 | 12,590 | 121,691 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2020 | 16,000 | 128,203 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 14 Oct 2020 | 16,000 | 128,700 (0%) | 0% | 1.0 | 16,160 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 14 Oct 2020 | 9,000 | 112,700 (0%) | 0% | 35.0 | 315,360 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.15 per share. | 14 Oct 2020 | 7,000 | 121,700 (0%) | 0% | 30.2 | 211,050 | Common Stock |
| Kymera Therapeutics Inc | Pamela Esposito | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2020 | 40,127 | 40,127 | - | - | Stock Option (Right to Buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 27.05 per share. | 31 Aug 2020 | 5,000 | 112,700 (0%) | 0% | 27.1 | 135,250 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 5,000 | 144,203 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 31 Aug 2020 | 5,000 | 117,700 (0%) | 0% | 1.0 | 5,050 | Common Stock |
| Replimune Group Inc | Pamela Esposito | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 85,450 | 85,450 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges